Two years ago, we argued that policymakers should abandon hope that biosimilar competition will reduce the prices of biologics after their period of market exclusivity has lapsed. The...
The P-quad proposal would set biologic drug prices based on production costs plus a fixed profit margin following completion of the initial FDA granted exclusivity period (or upon...
O’Day’s claim was translated in the WSJ that the discount would apply to the Medicare program, and in STAT and by ICER as it applying in Medicaid. These...
Partner with Verdant for rigorous, objective economic analysis.